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BACKGROUND AND OBJECTIVE
Background1-4

• CDC reports half of patients admitted to the hospital received at least 1 dose
of antibiotics from 2006-2012
• Approximately 32 million people in the United States have a documented
allergy to a beta-lactam (BL) antibiotic
• Approximately 10% of all US patients report having an allergic reaction to a BL
in their lifetime
• Fewer than 1% has a true IgE (immunoglobulin E) mediated allergy to a BL
• Over 80% of those patients with an IgE-mediated allergy lose sensitivity after
10 years
• Penicillin-skin testing cost: ~$220
• Per the CDC, carbapenem use increased by 37% from 2006-2012
• Carbapenems are rarely first line antibiotics, but are frequently used when first
line agents are excluded due to the patient's drug-allergies
• Carbapenem use is associated with increased healthcare costs and promotion
of antibiotic resistance
Objective
• Determine the beta-lactam (BL) allergy-risk stratification for patients at
Parkview Regional Medical Center with a documented allergy to a BL

RESULTS
Figure 1. Beta-lactam allergy-risk stratification2

Table 1. Patient characteristics

DESIGN AND METHODS

Design
• Observational, retrospective cohort study of patients with BL allergies to
evaluate the EMR determined risk level stratification of their BL allergy and
the correlations with carbapenem antibiotic use within 24 hours of admission
• Parkview Health IRB approved this quality improvement project
Methods
• Data was collected on any patient admitted to the general medical floors at
Parkview Regional Medical Center between August 3rd, 2020 and October
23rd, 2020
• We identified 235 unique documented beta lactam allergies of 197
hospitalized patients
• Data collected included
• Age
• Sex
• BL allergy and reaction type
• Duration of BL allergy
• Non-BL antibiotic allergies
• Skin test with reaction type
• Allergy-risk stratification (EMR)
• Non-antibiotic allergies
• Allergy-risk stratification (JAMA article)
• BL antibiotics received within 24 hours of current admission
• BL antibiotics received on previous admissions and in the outpatient
setting
• At minimum of one attempt for an interview via telephone was made for all
patients

Figure 2. Distribution of antibiotic use by risk stratification and admission

RESULTS
Figure 3. Percentage of patients aware of outpatient beta-lactam use

DISCUSSION AND CONCLUSION
Discussion
• Out of 235 unique beta lactam allergies identified, 192 (81.7%) of the
allergies had severity classifications of “not-specified" in the Parkview EMR
• 38 out of 197 (19.3%) patients had allergies to beta-lactam antibiotics with
the reaction type of “unknown,” making it harder to accurately stratify these
patients by reaction type
• For patients who received a beta-lactam within the first 24 hours of their
current admission, the likelihood the beta-lactam received was a
carbapenem are as follows:
• High risk = 79.9%
• Medium risk = 32.7%
• Low risk = 19.3%
Limitations
• Retrospective cohort study
• Data collection via chart review
• No in-person interviewing due to the COVID-19 pandemic, only telephonebased interviewing permitted (67.5% of patients reached via telephone)
Future Directions
• Study results will facilitate change in the Parkview Health System regarding
allergy classification, allergy risk stratification, and prescribing habits
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